Arcus Biosciences has been granted a patent for solid forms, solvates, and hydrates of Compound I, along with methods of production and application. The patent claim specifically covers a solid form of Compound I. GlobalData’s report on Arcus Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcus Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Arcus Biosciences's grant share as of May 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Solid form of compound i
A recently granted patent (Publication Number: US11993584B2) discloses a solid form of Compound I characterized by specific X-ray powder diffraction patterns and unit cell dimensions. The patent claims also include a pharmaceutical composition comprising the solid form of Compound I and a pharmaceutically acceptable excipient, as well as a method of treating diseases mediated by adenosine A2A and A2B receptors by administering the solid form of Compound I to a subject in need.
Furthermore, the patent claims cover the treatment of various cancers and immune-related diseases using the solid form of Compound I, with specific mentions of prostate, colon, rectal, pancreatic cancers, among others. The method also includes the administration of additional therapeutic agents, such as immune checkpoint inhibitors, to enhance the treatment efficacy. The patent also extends to the treatment of specific cancer types like non-small-cell lung carcinoma, melanoma, basal cell carcinoma, lymphoma, leukemia, small-cell lung carcinoma, and Kaposi's sarcoma, showcasing the broad applicability of the solid form of Compound I in combating a range of diseases mediated by the adenosine A2A and A2B receptors.
To know more about GlobalData’s detailed insights on Arcus Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
